Today, $NTLA announced Q3 2020 financial results and that we remain on track to dose the first patient with NTLA-2001 for the treatment of #ATTR using #CRISPR /Cas9 by the end of the year. Full press release here: https://t.co/3ruEn86Ivh #genomeediting https://t.co/UHdqleVdQg